Background
==========

Three-dimensional myocardial perfusion MRI offers better myocardial coverage than conventionally used two-dimensional methods. bSSFP three-dimensional myocardial perfusion MRI at 3 Tesla potentially offers further improvement of signal characteristics and may enhance the use of three-dimensional myocardial perfusion MRI for clinical application.

Methods
=======

Twenty-five healthy volunteers and 2 patients were included upon written informed consent and local ethics committee approval. Dynamic contrast-enhanced 3D bSSFP perfusion imaging was performed on a 3 Tesla MRI scanner equipped with dual-source RF transmission technology (MultiTransmit; Philips Healthcare, The Netherlands).

Results
=======

Local RF Shimming with dual source RF transmission significantly improved B1 field homogeneity (P=0.0107). For bSSFP perfusion imaging, it allowed a reduction of TR from 3.4 to 2.2 ms at the same flip angle. Image quality was similar for TFE and bSSFP but there were more artefacts for bSSFP (Figure [1](#F1){ref-type="fig"}).
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Compared with an equivalent 3D spoiled gradient echo method (TFE), mean SNR was (30.4 vs 24.4, respectively, P=0.24), but signal homogeneity measured in the myocardium was improved (14.98% vs 11.15%, respectively, p=0.015).

Conclusions
===========

Three-dimensional bSSFP myocardial perfusion MRI using local RF Shimming with dual-source RF transmission at 3 Tesla is feasible with improved signal characteristics. Image artifacts however remain an important limitation.
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